An interventional study of Pulmonary Vein Isolation and Additional Left Atrial Posterior Wall Ablation in Atrial Fibrillation (AF), sponsored by Ewha Womans University Mokdong Hospital. Enrolling by invitation at 1 site in South Korea. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Ewha Womans University Mokdong Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 51st largest by planned enrollment of the 144 interventional ones that give a count, is one of 17 that started in 2026, is one of 91 with no phase, reaches primary completion later than 50 of the 68 other live ones, and was the 172nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 22 · Phase 4 22
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 482 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 144 interventional studies, 1,181 across the 65 observational. Of the 101 that completed or were terminated, 33 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 209 have an industry lead sponsor. The 10 most frequent:
Ewha Womans University Mokdong Hospital is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Ewha Womans University Mokdong Hospital has 8 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
11 of the studies in Atrial Fibrillation with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07641582Seoul St. Mary's HospitalPrediction of Atrial Fibrillation Using Polygenic Risk Score | 2026-12-30 |
| NCT05507749Seoul National University HospitalCyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring | 2026-12-31 |
| NCT07947498Chungnam National University HospitalPrognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction | 2026-12-31 |
| NCT05794386Seoul National University HospitalSCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To date, no optimal treatment has been established to improve outcomes in patients with persistent atrial fibrillation. The safety and efficacy of pulsed-field ablation (PFA) have been demonstrated in several studies, and its clinical application is expanding.
- In patients with persistent atrial fibrillation, can the addition of posterior wall isolation (PWI) following pulmonary vein isolation (PVI) using PFA reduce recurrence?
Participants will:
Atrial fibrillation is a major cardiovascular disease, and catheter ablation has become an established rhythm-control strategy that provides superior outcomes compared with pharmacological therapy in patients with drug-refractory atrial fibrillation. Although the efficacy of pulmonary vein isolation (PVI) is well established in patients with paroxysmal atrial fibrillation, the effectiveness of additional ablation strategies beyond PVI remains uncertain in patients with persistent atrial fibrillation.
Several studies have suggested that left atrial posterior wall isolation (PWI) may help reduce recurrence; however, conventional thermal ablation techniques have been limited by technical challenges in achieving durable lesion formation. Pulsed field ablation (PFA) is a nonthermal ablation technology that creates selective myocardial lesions, enabling rapid and consistent lesion formation while minimizing injury to surrounding tissues.
This study aims to prospectively and randomly compare PVI alone using PFA with PVI followed by additional PWI in patients with persistent atrial fibrillation. By evaluating recurrence rates, procedure time, complications, atrial fibrillation burden, and patient satisfaction, this study seeks to identify the optimal ablation strategy for patients with persistent atrial fibrillation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo additional left atrial posterior wall isolation using pulsed field ablation. Before completion of the procedure, electrical isolation of both the pulmonary veins and the left atrial posterior wall will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.
Procedure: Pulmonary Vein Isolation · Procedure: Additional Left Atrial Posterior Wall Ablation
Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo no additional left atrial posterior wall isolation. Before completion of the procedure, electrical isolation of the pulmonary veins will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.
Procedure: Pulmonary Vein Isolation · Procedure: Non-PV trigger test
1. Pulmonary vein isolation (PVI) is performed as the primary procedure. 2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. 3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization.
Also known as: PVI
1. Additional left atrial posterior wall ablation is performed. 2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved). 3. Post-procedural rhythm monitoring follows the study protocol.
Also known as: Posterior box isolation
1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed. 2. Post-procedural rhythm monitoring follows the study protocol.
Recurrence of atrial tachyarrhythmia
Freedom from documented AF/AT/AFL ≥30 seconds at 12 months post-procedure
Time frame: Within 12 months after the procedure, excluding the first 4-week blanking period
Peri-procedural complication
Major ; brain hemorrhage, thromboembolism , atrial -esophageal fistula, pericardial effusion, tamponade, irreversible phrenic nerve palsy, bleeding requiring transfusion, Pulmonary Vein Stenosis: Minor ; puncture site bleeding not requiring transfusion , groin hematoma, reversible phrenic nerve palsy
Time frame: Within 12 months after the procedure
Total procedure time
total procedure time
Time frame: Periprocedural
Length of hospital stay
Length of hospital stay
Time frame: Within one year from the time of enrollment
Atrial fibrillation burden assessed by Holter ECG
Atrial fibrillation burden will be calculated as the percentage of the total analyzable Holter ECG monitoring time spent in atrial fibrillation or atrial tachyarrhythmia. Values range from 0% to 100%, with higher percentages indicating a greater atrial fibrillation burden and therefore a worse outcome.
Time frame: Within 12 month from the time of enrollment
patient satisfaction
Atrial Fibrillation Effect on Quality-of-Life(AFEQT)
Time frame: Within one year from the time of enrollment
Plan to share: No — Individual participant data (IPD) will not be shared due to concerns regarding patient confidentiality and the lack of specific consent for data sharing obtained during the study enrollment process.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ewha Womans University Mokdong Hospital